Sign up to save your podcasts
Or
Share AMD 2022 Jul: AREDS2 Long-Term Outcomes: Lutein, Zeaxanthin, and AMD Progression
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AMD 2022 Jul: AREDS2 Long-Term Outcomes: Lutein, Zeaxanthin, and AMD Progression
AREDS2 Long-Term Outcomes: Lutein, Zeaxanthin, and AMD Progression
Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W; AREDS2 Research Group. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. doi: 10.1001/jamaophthalmol.2022.1640. PMID: 35653117; PMCID: PMC9164119.
https://pmc.ncbi.nlm.nih.gov/articles/pmid/35653117/
View all episodes
By Dr Michael Nelson, OD FAAOAREDS2 Long-Term Outcomes: Lutein, Zeaxanthin, and AMD Progression
Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W; AREDS2 Research Group. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. doi: 10.1001/jamaophthalmol.2022.1640. PMID: 35653117; PMCID: PMC9164119.
https://pmc.ncbi.nlm.nih.gov/articles/pmid/35653117/